Back to Trials
NCT06080061PHASE1Recruiting

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Stanford University

Start Date

10/25/2023

Completion Date

12/1/2026

Summary

The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy * ECOG performance status of 0-2 * Age ≥ 18 years old * Ability to understand and the willingness to personally sign the written IRB approved informed consent document * Estimated life expectancy of 12 weeks or longer Exclusion Criteria: * Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist * Age \< 18 years old * Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree * Diagnosis of interstitial pulmonary fibrosis * Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields

Interventions

RADIATION

Hypofractionated accelerated radiation therapy

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Lung Cancer

Locations

Stanford University

Palo Alto, California 94305

United States

Stanford Cancer Center South Bay

San Jose, California 95124

United States